Immunogens for HIV vaccination
US-9988425-B2 · Jun 5, 2018 · US
US11110091B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11110091-B2 |
| Application number | US-201816201221-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 27, 2018 |
| Priority date | Dec 9, 2008 |
| Publication date | Sep 7, 2021 |
| Grant date | Sep 7, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided are modulators of TLRs of Formula II: pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.
Opening claim text (preview).
We claim: 1. A compound of Formula II: or a pharmaceutically acceptable salt thereof, wherein: Y—Z is —CR 4 R 5 —CR 4 R 5 ; L 1 is —NH— or —O—; R 1 is C 1 -C 6 alkyl C 3 -C 12 saturated carbocyclyl, C 4 -C 20 saturated carbocyclylalkyl, or C 6 -C 20 arylalkyl; X 1 is —CH 2 ; D is phenyl substituted with -L 2 -NR 6 R 7 ; each L 2 is independently C 1 -C 6 alkylene; each R 3 is independently halogen, cyano, or C 1 -C 6 haloalkyl; n is 0 or 1; R 4 and R 5 are each H; R 6 and R 7 are each independently H, C 1 -C 6 alkyl, or C 4 -C 20 saturated carbocyclylalkyl, —C(O)R 8 , —S(O)R 8 , —S(O) 2 R 8 , or —C(O)OR 8 ; or R 6 and R 7 , taken together with the nitrogen to which they are both attached, form a 4-6 membered saturated heterocycle comprising 0 to 2 heteroatoms selected from N, O, or S; and R 8 is H or C 1 -C 6 alkyl. 2. The compound of claim 1 selected from the group consisting of or a pharmaceutically acceptable salt thereof. 3. A compound of formula: or a pharmaceutically acceptable salt thereof.
Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title
Drugs for disorders of the respiratory system · CPC title
for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title
Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols · CPC title
Interferons {[IFN]} · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.